63 results on '"Thaçi, Diamant"'
Search Results
2. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
3. Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
4. Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study
5. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial
6. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
7. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial
8. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
9. 34321 Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial
10. 33055 Guselkumab efficacy and safety through 5 years among psoriasis patients with and without metabolic syndrome at baseline: Results from VOYAGE 1 and VOYAGE 2
11. 33025 Stability of PASI <3 response to tildrakizumab through 5 years: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials
12. 33765 Phase 1b randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of GLPG3667 in patients with moderate-to-severe plaque psoriasis
13. Efficacité du bimékizumab dans le psoriasis en plaques modéré à sévère dans différents sous-groupes de patients : résultats groupés de trois études de phase 3, multicentriques randomisées en double aveugle
14. Deucravacitinib (DEUC), inhibiteur sélectif de la tyrosine kinase 2 (TYK2) oral, comparé au placebo et à l’aprémilast dans le psoriasis du cuir chevelu : analyse des essais de phase 3 POETYK PSO-1 et PSO-2
15. Le deucravacitinib, inhibiteur sélectif de la tyrosine kinase 2 (TYK2), comparé au placebo et à l’aprémilast dans le psoriasis en plaques : efficacité en fonction des caractéristiques de la maladie à l’inclusion dans les essais POETYK PSO-1 et PSO-2
16. 26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: Pooled analysis from two randomized phase 3 studies
17. 27464 Bimekizumab vs adalimumab in plaque psoriasis: Higher efficacy translates into improvements in quality of life in the BE SURE multicenter, randomized, double-blinded phase 3 trial
18. 25532 Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
19. 26874 Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial
20. 27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial
21. 26880 Long-term efficacy and safety data for dupilumab in a phase 3, open-label extension trial (LIBERTY AD PED-OLE) in patients aged ≥6 to <12 years with uncontrolled, moderate-to-severe atopic dermatitis (AD)
22. 28194 Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: Pooled results from two phase 3 studies
23. 26592 Characterization of response clusters identified by unsupervised machine learning: A post hoc analysis of the head-to-head ECLIPSE trial of guselkumab and secukinumab in patients with moderate-to-severe psoriasis
24. 26573 Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
25. 27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: Pooled subgroup analysis from two randomized phase 3 studies
26. 25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
27. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
28. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)
29. A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action
30. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
31. 18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial
32. 15807 Efficacy of tildrakizumab in patients with moderate to severe psoriasis according to disease duration: Pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials at week 28
33. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial
34. Secukinumab-induced chronic discoid lupus erythematosus
35. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial
36. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
37. Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study
38. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
39. Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks
40. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)
41. Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
42. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)
43. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
44. Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Allergic Rhinitis: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)
45. Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis”
46. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)
47. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial
48. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
49. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
50. Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.